EVONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as EVOTF
Evotec SE
Financials through fiscal 2024, year ended Dec 31, 2024Last filing: 20-F on Apr 8, 2026
$1.42+0.04 (+2.90%)
Close on Oct 19, 2026
Share price
−$2.46 (−63.40%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Evotec SE grew revenue 2.0% to €796.97M over fiscal 2024. Free cash flow was -€99.25M.
Revenue
€796.97M
+2.0% vs. a year earlier
Operating income
-€142.52M
FY2024
Free cash flow
-€99.25M
FY2024
EPS, diluted
-1.11 EUR
FY2024
Key statistics
Valuation at the latest close; fundamentals over fiscal 2024, balances at Dec 31, 2024
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- €796.97M
- EPS, diluted
- -1.11 EUR
- Free cash flow
- -€99.25M
Valuation needs the share price. It fills in once daily prices are connected and converted from EUR.
Seven years at a glance
Fiscal years 2018 to 2024, EUR
Revenue
€796.97M+2.0% YoY
Gross profit
€114.88M-34.4% YoY
Operating income
-€142.52M
Net income
–
EPS, diluted
-1.11 EUR
Free cash flow
-€99.25M
Reported period